Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses.
Name:
SupplementaryInformation.pdf
Size:
129.9Kb
Format:
PDF
Description:
supplementary information
Name:
SupplFigure1.tif
Size:
2.704Mb
Format:
TIFF image
Description:
supplemental figure S1
Name:
SupplFigure2.tif
Size:
30.02Kb
Format:
TIFF image
Description:
supplemental figure S2
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Siddharta, AnindyaPfaender, Stephanie
Vielle, Nathalie Jane
Dijkman, Ronald
Friesland, Martina
Becker, Britta
Yang, Jaewon
Engelmann, Michael
Todt, Daniel
Windisch, Marc P
Brill, Florian H
Steinmann, Joerg
Steinmann, Jochen
Becker, Stephan
Alves, Marco P
Pietschmann, Thomas
Eickmann, Markus
Thiel, Volker
Steinmann, Eike

Issue Date
2017-03-15
Metadata
Show full item recordAbstract
The World Health Organization (WHO) published 2 alcohol-based formulations to be used in healthcare settings and for outbreak-associated infections, but inactivation efficacies of these products have not been determined against (re-)emerging viruses. In this study, we evaluated the virucidal activity of these WHO products in a comparative analysis. Zika virus (ZIKV), Ebola virus (EBOV), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) as (re-)emerging viral pathogens and other enveloped viruses could be efficiently inactivated by both WHO formulations, implicating their use in healthcare systems and viral outbreak situations.Citation
Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. 2017, 215 (6):902-906 J. Infect. Dis.Affiliation
TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung gmbH, Feodor-Lynen Str. 7, 30625 Hannover, Germany.PubMed ID
28453839Type
ArticleLanguage
enISSN
1537-6613ae974a485f413a2113503eed53cd6c53
10.1093/infdis/jix046
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
Related articles
- Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine.
- Authors: Pregelj L, Hine DC, Oyola-Lozada MG, Munro TP
- Issue date: 2020 Sep
- Remdesivir against COVID-19 and Other Viral Diseases.
- Authors: Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J
- Issue date: 2020 Dec 16
- Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses.
- Authors: Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K
- Issue date: 2015 Sep 17
- Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential.
- Authors: Zumla A, Dar O, Kock R, Muturi M, Ntoumi F, Kaleebu P, Eusebio M, Mfinanga S, Bates M, Mwaba P, Ansumana R, Khan M, Alagaili AN, Cotten M, Azhar EI, Maeurer M, Ippolito G, Petersen E
- Issue date: 2016 Jun
- Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).
- Authors: Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H
- Issue date: 2016 Apr 22